Trial Profile
Phase I/II study of bortezomib plus Lenalidomide and dexamethasone (Once weekly VRd-21) for relapsed and/or refractory multiple myeloma (Once weekly VRd-21, I/II VRD for MM)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 17 May 2016
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Lenalidomide (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 23 Feb 2015 Status changed from recruiting to active, no longer recruiting, according to University Hospital Medical Information Network - Japan
- 12 Mar 2014 New trial record